Use of poly (adp-ribose) polymerase inhibitors (PARPi) in metastatic castration resistant prostate cancer (mCRPC) patients stratified by homologous recombination repair mutations. This is an ASCO ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Don’t ...

Oncologists’ Attitudes and Practice of Addressing Diet, Physical Activity, and Weight Management With Patients With Cancer: Findings of an ASCO Survey of the Oncology Workforce The cohort consisted of ...

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited—and time matters. As the disease progresses, the window for effective, less ...

Studies have reported healthcare costs before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in commercially insured populations, but no information is available about ...

Don’t tell Bryan Johnson, the tech CEO famously obsessed with not dying, but the key to living longer for men just might be getting your nuts surgically removed. That’s the surprising finding in a new ...